Publications by authors named "Y Momii"
Article Synopsis
- The study investigates treatment options and costs for malignant brain tumors (GBM and PCNSL) in Japan through a survey of 47 institutions.
- For GBM, the most common treatment is 'Surgery + radiotherapy with temozolomide', costing approximately 7.50 million JPY, with additional treatments raising costs significantly.
- PCNSL treatments, especially R-MPV therapy, also incur high costs, with some regimens exceeding 1 million JPY per month, highlighting the need for better cost-effectiveness assessments in future health studies.
Article Synopsis
- Pineal parenchymal tumors of intermediate differentiation (PPTIDs) are rare brain tumors, making up less than 1% of CNS tumors, which creates challenges for diagnosis and treatment.* -
- A study across 11 institutions identified 28 patients with PPTID, with findings showing a median age of 49, a predominance of females, and a gross total resection success rate of 46%.* -
- The study concluded that female sex and gross total resection are important factors for better patient outcomes, with a high occurrence of leptomeningeal recurrences and KBTBD4 mutations present in most patients.*
Objective: An autologous formalin-fixed tumor vaccine (AFTV) derived from resected glioblastoma (GBM) tissue can be used against unidentified tumor antigens. Thus, the authors conducted a multicenter double-blind phase IIb trial to investigate the efficacy of an AFTV.
Methods: Eligible patients were adults with supratentorial GBMs, 16-75 years of age, with Karnofsky Performance Scale (KPS) scores ≥ 60%, and no long-term steroid administration.
Objectives: The anticonvulsant and antioxidant effects of lamotrigine on status epilepticus (SE) are incompletely understood. We assessed these effects of lamotrigine on pilocarpine (Pilo)-induced SE in mice.
Methods: Male C57BL/J6 mice were assigned to three groups: the control group, Pilo (400 mg/kg, s.
Background: The goal was to determine whether the addition of temozolomide (TMZ) to the standard treatment of high-dose methotrexate (HD-MTX) and whole-brain radiotherapy (WBRT) for primary central nervous system lymphoma (PCNSL) improves survival.
Methods: An open-label, randomized, phase III trial was conducted in Japan, enrolling immunocompetent patients aged 20-70 years with histologically confirmed, newly diagnosed PCNSL. After administration of HD-MTX, patients were randomly assigned to receive WBRT (30 Gy) ± 10 Gy boost (arm A) or WBRT ± boost with concomitant and maintenance TMZ for 2 years (arm B).